NCT06082076

Brief Summary

The aim of the study is to compare the effectiveness of prophylactic use of intravenous (IV) dexmedetomidine VS ketamine and meperidine(as a control group) in prevention of shivering associated with intrathecal anesthesia in patients undergoing knee arthroscopy

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Nov 2023

Shorter than P25 for phase_2

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 8, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 13, 2023

Completed
19 days until next milestone

Study Start

First participant enrolled

November 1, 2023

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

October 13, 2023

Status Verified

October 1, 2023

Enrollment Period

1 year

First QC Date

October 8, 2023

Last Update Submit

October 8, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of shivering

    Incidence of shivering post intrathecal anesthesia is recorded

    During operation time

Study Arms (3)

Group D (dexmedetomidine group)

ACTIVE COMPARATOR
Drug: Dexmedetomidine

Group K (ketamine group)

ACTIVE COMPARATOR
Drug: Ketamine

Group C (control group)

PLACEBO COMPARATOR
Drug: Meperidine

Interventions

Patients will receive dexmedetomidine 0.5 mcg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia

Group D (dexmedetomidine group)

Patient will will receive ketamine 0.5 mg/kg diluted in 10 mL of NS given as IV infusion over 10 min before induction of spinal anesthesia

Group K (ketamine group)

If the tested drug hasn't stopped shivering patient will receive 0.25 mg/kg meperidine

Group C (control group)

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • \- BMI 20-30 Scheduled patients for knee arthroscopy under spinal anesthesia. American Society of Anesthesiologists (ASA) physical status: I and II

You may not qualify if:

  • Patient refusal Aged less than 18 years or lesser than 150 cm in height Pregnant woman Allergy to the studied drugs. Patients with contraindications to spinal anesthesia. Patients with advanced decompensated cardiac, respiratory,renal or hepatic diseases, ASA III-IV Coagulopathy or thrombocytopenia CNS diseases as epilepsy, stroke or psychiatric illness.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

DexmedetomidineKetamineMeperidine

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsIsonipecotic AcidsAcids, HeterocyclicPiperidines

Study Officials

  • Essam Ez Abdelhakeem, Professor

    Assiut University

    STUDY DIRECTOR
  • Seham Mo Moeen, Professor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Ahmed Ga Mohammed, Resident

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mohammed Mohammed

Study Record Dates

First Submitted

October 8, 2023

First Posted

October 13, 2023

Study Start

November 1, 2023

Primary Completion

November 1, 2024

Study Completion

December 1, 2024

Last Updated

October 13, 2023

Record last verified: 2023-10